º¸¸£ÇǸ°Àº Áö¹æÈ°¼ºÈ ¼ººÐÀ¸·Î ³ôÀº ¾ÈÀü¼º°ú ¼º´ÉÀ¸·Î Àü¼¼°èÀûÀ¸·Î ³Î¸® »ç¿ëµÇ´Â ¼ººÐÀÔ´Ï´Ù. º¸¸£ÇǸ°Àº È£¸£¸óÈ°¼º¿¡ ¿µÇâÀ» ÁÖÁö ¾Ê´Â ÇÇÅ佺Å×·ÑÀÔ´Ï´Ù. ¾Æ½Ã¾ÆÁö¿ª¿¡ ÀÚ»ýÇÏ´Â ½Ä¹°'Áö¸ð'ÀÇ »Ñ¸®¿¡¼ ÃßÃâÇÑ ¼ººÐÀÔ´Ï´Ù. Promotes body volume by a cosmetic lipofilling-like effect.
Demonstrated cosmetic activity (In vitro)
1. The proliferation of adipocytes in the differentiation phase: o 20.5% increase with a concentration equivalent to 0.5% VOLUFILINE¢â o 35.2% increase with a concentration equivalent to 2% VOLUFILINE¢â
2.The differentiation of pre-adipocytes as determined by G3PDH activity: o 103% increase with a concentration equivalent to 0.5% VOLUFILINE¢â o 535% increase with a concentration equivalent to 1.75% VOLUFILINE¢â
3.Lipid uptake in cultured adipocytes 3T3-L1 and human adipocytes: o For cultured adipocytes 3T3-L1: 492% increase with a concentration equivalent to 1.75% VOLUFILINE¢â o For human adipocytes: 641% increase with a concentration equivalent to 1% VOLUFILINE¢â
4. Adipocyte volume: o 26-fold increase in cell volume with 1.5% VOLUFILINE¢â
Demonstrated cosmetic activity (In vivo)
28¸íÁö¿øÀÚ¿¡°Ô 56Àϵ¿¾È ÀÓ»ó ½ÃÇèÀ» Çß´Ù. 18¼¼~35¼¼ ¿©¼ºÀ» ¼±Á¤ÇØ 5%ÇÔÀ¯ °ÖŸÀÔÅ©¸²À» ÇÏ·ç¿¡ µÎ ¹ø ÇÑÂÊ °¡½¿¿¡¸¸ ¹Ù¸¥´Ù. ´ëÁ¶±ºÀ¸·Î ÇÑÂÊ¿¡´Â ¹Ù¸£Áö ¾Ê¾Ò½À´Ï´Ù. (½ÇÇè±â°£µ¿¾È ¸ö¹«°Ô´Â 3°³¿ù µ¿¾È À¯Áö, ÀÓ½ÅÇϰųª ¼öÀ¯¸¦ ÇÏÁö ¾ÊÀ½. È£¸£¸óÀÌ ±ÔÄ¢ÀûÀÌ°í ±¸°ÇÇÀÓÀ» ÇÏÁö ¾ÊÀº »óÅÂ.)
°á°ú : 28ÀÏ ÈÄ 5% º¸¸£ÇǸ° ÇÔÀ¯Å©¸²À» ¹Ù¸¥ ÂÊÀº 1.4% º¼·ý Áõ°¡
56ÀÏ ÈÄ 2.2% º¼·ý Áõ°¡
Áö¿øÀÚ Áß »óÀ§ 25%´Â 28ÀÏ ÈÄ 6.4% º¼·ý Áõ°¡, 56ÀÏ ÈÄ¿¡´Â 8.4%Áõ°¡
È°¿ë ·¹½ÃÇÇ ¾È³»: º¸¸£ÇǸ° 100 ¾ÚÇÃ-º¸¸£ÇǸ° ¿ø¾×À» ±âÁ¸¿¡ »ç¿ëÇÏ´ø ¿ÀÀÏ, ·Î¼Ç, Å©¸² µî¿¡ Àû¿ëÇØ »ç¿ëÇÑ´Ù. º¸¸£ÇǸ°5 ¼öºÐ¿¡¼¾½º-ÁغñÁß^^
|